logo
Overdose deaths fell 27% in 2024— the largest one-year decline ever

Overdose deaths fell 27% in 2024— the largest one-year decline ever

Fast Company14-05-2025

There were 30,000 fewer U.S. drug overdose deaths in 2024 than the year before — the largest one-year decline ever recorded.
An estimated 80,000 people died from overdoses last year, according to provisional Centers for Disease Control and Prevention data released Wednesday. That's down 27% from the 110,000 in 2023.
The CDC has been collecting comparable data for 45 years. The previous largest one-year drop was 4% in 2018, according to the agency's National Center for Health Statistics.
All but two states saw declines last year, with Nevada and South Dakota experiencing small increases. Some of the biggest drops were in Ohio, West Virginia and other states that have been hard-hit in the nation's decades-long overdose epidemic.
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors. Among the most cited:
— Increased availability of the overdose-reversing drug naloxone.
— Expanded addiction treatment.
— Shifts in how people use drugs.
— The growing impact of billions of dollars in opioid lawsuit settlement money.
— The number of at-risk Americans is shrinking, after waves of deaths in older adults and a shift in teens and younger adults away from the drugs that cause most deaths.
Still, annual overdose deaths are higher than they were before the COVID-19 pandemic. In a statement, the CDC noted that overdoses are still the leading cause of death for people 18-44 years old, 'underscoring the need for ongoing efforts to maintain this progress.'
Some experts worry that the recent decline could be slowed or stopped by reductions in federal funding and the public health workforce, or a shift away from the strategies that seem to be working.
'Now is not the time to take the foot off the gas pedal,' said Dr. Daniel Ciccarone, a drug policy expert at the University of California, San Francisco.
The provisional numbers are estimates of everyone who died of overdoses in the U.S., including noncitizens. That data is still being processed, and the final numbers can sometimes differ a bit. But it's clear that there was a huge drop last year.
Experts note that there have been past moments when U.S. overdose deaths seemed to have plateaued or even started to go down, only to rise again. That happened in 2018.
But there are reasons to be optimistic.
Naloxone has become more widely available, in part because of the introduction of over-the-counter versions that don't require prescriptions.
Meanwhile, drug manufacturers, distributors, pharmacy chains and other businesses have settled lawsuits with state and local governments over the painkillers that were a main driver of overdose deaths in the past. The deals over the last decade or so have promised about $50 billion over time, with most of it required to be used to fight addiction.
Another settlement that would be among the largest, with members of the Sackler family who own OxyContin maker Purdue Pharma agreeing to pay up to $7 billion, could be approved this year.
The money, along with federal taxpayer funding, is going to a variety of programs, including supportive housing and harm reduction efforts, such as providing materials to test drugs for fentanyl, the biggest driver of overdoses now.
But what each state will do with that money is currently at issue. 'States can either say, 'We won, we can walk away'' in the wake of the declines or they can use the lawsuit money on naloxone and other efforts, said Regina LaBelle, a former acting director of the Office of National Drug Control Policy. She now heads an addiction and public policy program at Georgetown University.
President Donald Trump's administration views opioids as largely a law enforcement issue and as a reason to step up border security. That worries many public health leaders and advocates.
'We believe that taking a public health approach that seeks to support — not punish — people who use drugs is crucial to ending the overdose crisis,' said Dr. Tamara Olt, an Illinois woman whose 16-year-old son died of a heroin overdose in 2012. She is now executive director of Broken No Moore, an advocacy organization focused on substance use disorder.
Olt attributes recent declines to the growing availability of naloxone, work to make treatment available, and wider awareness of the problem.
Kimberly Douglas, an Illinois woman whose 17-year-old son died of an overdose in 2023, credited the growing chorus of grieving mothers. 'Eventually people are going to start listening. Unfortunately, it's taken 10-plus years.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fast Five Quiz: Opioid Use Disorder
Fast Five Quiz: Opioid Use Disorder

Medscape

time35 minutes ago

  • Medscape

Fast Five Quiz: Opioid Use Disorder

Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns
RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

Yahoo

timean hour ago

  • Yahoo

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

The Brief U.S. Health Secretary Robert F. Kennedy Jr. has replaced the government's vaccine advisory panel with eight new appointees. The new members include vocal critics of COVID-19 vaccines and pandemic lockdowns, such as Dr. Robert Malone and Dr. Martin Kulldorff. Public health groups have raised concerns that Kennedy's changes could undermine long-standing vaccination policies. NEW YORK - U.S. Health Secretary Robert F. Kennedy Jr. has named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. His selections include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. RELATED: RFK Jr. ousts entire CDC vaccine panel Kennedy made the announcement in a social media post on Wednesday. The backstory Kennedy's decision to "retire" the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. Dig deeper The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Big picture view The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. The Source The Associated Press contributed to this report. The information in this story comes from a social media announcement made by U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday, in which he introduced eight new members to the federal vaccine advisory panel. This story was reported from Los Angeles.

Matthew 25 unveils mobile STD testing unit
Matthew 25 unveils mobile STD testing unit

Yahoo

timean hour ago

  • Yahoo

Matthew 25 unveils mobile STD testing unit

HENDERSON, Ky (WEHT) – The non-profit organization Matthew 25 held a ribbon cutting to celebrate its campaign to help prevent, educate and treat people in the Tri-State with Sexual Transmitted Diseases. Last August, The Centers for Disease Control and Prevention granted $3,000,000 in funding to the organization. Matthew 25 used a large portion of that grant in partnership with Mission Mobile Medical to customize the treatment center. As for why this was needed, Chief Executive Officer, Courtney Woolfork, said, 'We have clinics in Owensboro, Henderson, and Bowling Green. But everything in between is really hard for people to get access to, because there isn't public transportation always.' The non-profit covers 25 counties in Kentucky and 12 in Indiana and officials say that they have seen STD trends increasing in those regions. Woolfork says that trends like these are why it's so beneficial to have a mobile treatment unit that can serve vulnerable areas. The mobile unit will also have PREP pills available to those who have had a Sexually Transmitted Illnesses. Matthew 25 urges those who have come in contact with an STD or STI to get this pill to lessen their chances of contracting HIV in the future. Over the next couple months, Woolfork and her team plan on traveling to 25 counties in the Tri-State. March 27 will kick off the road trip, as they will be in Owensboro, Kentucky for National HIV Testing Day. Although they are fighting an uphill battle the mission statement is clear, 'Meeting people where they are and however they are.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store